The novel group of 4-GABA-3-nitrocoumarines, 1-thiocoumarines, quinolone-2-ones, and their derivatives was designed as potential anticonvulsants using GABA pharmacophore and corresponding heterocyclic moieties. A number of compounds of this group were synthesized and studied in the maximum electroshock seizure (MES) test and in the model of primary-generalized convulsions caused by subcutaneous pentylenetetrazole
使用
GABA药效团和相应的杂环部分,将新型的4-
GABA-
3-硝基
香豆素,1-
硫代
香豆素,
喹诺酮-2-酮及其衍
生物设计为潜在的抗惊厥药。合成了该组中的许多化合物,并在最大电击惊厥(
MES)测试中以及在小鼠皮下
戊四氮(sc
PTZ)引起的原发性惊厥模型中进行了研究。在
MES测试中发现活性最高的化合物是1a(N-(
3-硝基
香豆素-4-基)-
4-氨基丁酸),剂量范围为60-80 mg / kg,可增加存活动物的数量与对照组的60%相比,后者的存活率为10%。化合物1d(N-(3,6-二硝基
香豆素-4-基)-
4-氨基丁酸甲酯)剂量为10–40 mg / kg和3a(N-(
3-硝基-2-氧代-1,2-二氢
喹啉) 12.5 mg / kg剂量的-4-基)-
4-氨基丁酸甲酯)在sc
PTZ测试中具有最明显的抗惊厥作用。